Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: sjemmeri who wrote (936)	5/26/2005 10:04:36 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Re: TELK On its weekly chart,the stock hasn't been able to get off its long term down trend coming from the April 2004 H at the 29.67 level in spite of occasional spikes like the ones in June,October and November 2004,and the more recent one on May 13.<g> bigcharts.marketwatch.com On its daily chart, the stock closed its March 16 down-gap as it bounced up from its April 1 L of 14.29 and in early May it started to get off the near term downtrend coming from the October 4 H at 24.08 and after the aforementioned spike on May 13 with an intra-day H of 19.87, it almost tested the January 21 H of 20.10, but since then it resumed its down-trend and the stock is now testing the April 1 L.<g> bigcharts.marketwatch.com I would wait on buying until we get more evidence that the April L (14.29) is going to hold and the stock starts showing some signs that it will start an up-move.<g> It hasn't been able to get an up-move started in spite of the two presentations in NY this week and the encouraging results reported last week of TELCYTA's P1-2a on patients with NSCLC. It seems to have enough cash, reportedly around 258.2M or almost $5/share and only $2M of LTD with a Debt/Eqt Ratio around 0.008, to be able to keep burning cash for a while at its present rate.(The estimated loss for the current year is around $1.72/share (about $0.12/share more than last Yr.) and for 2006 the EL is somewhat lower, around $1.43/share. Besides the P1-2a on TELCYTA that it announce last week, TELK also has 3 PIIIs going on TELCYTA (Two on patients with ovarian Ca and one on patients with advanced NSCLC ) and is also conducting a PII on patients with NSCLC and a PII with its TELINTRA in patients with MDS. The PSML and PS on TELK at present: 14.67 14.90 15.62 16.34 and 18.64 all on a frank DOWTREND. Bernard